Non-invasive exploration of metabolic profile of lung cancer with Magnetic Resonance Spectroscopy and Mass Spectrometry

• Published in: Contemporary clinical trials communications 2019-12, Vol.16, p.100445-100445, Article 100445
• Main Authors: Ahmed, Naseer, Kidane, Biniam, Wang, Le, Tan, Lawrence, Buduhan, Gordon, Srinathan, Sadeesh, Aliani, Michel
• Format: Article
• Language: English
• Subjects: Biomarkers; Lung cancer; Metabolomics; Other
• ISSN: 2451-8654; 2451-8654
• DOI: 10.1016/j.conctc.2019.100445

AbstractBackgroundLung cancer is a major cause of global morbidity and mortality. Current low dose CT screening is invasive and its role remains contentious. There are no known biomarkers to monitor treatment response, detect disease recurrence and patient selection for adjuvant treatment after curative surgical resection. Hence there is an urgent need to explore non-conventional and noninvasive tools to develop novel biomarkers to improve the outcome of this lethal cancer. MethodsThis is an ongoing exploratory and translational study involving collection of bio fluids from 50 patients with early stage non-small cell lung cancer before and after surgical resection. The primary Objective is to identify cancer specific metabolome in body fluids - sputum, exhaled breath condensate, blood and urine of the patients with early stage non-small. cell lung cancer (NSCLC) using Magnetic Resonance Spectroscopy (MRS) and Mass Spectroscopy (MS). ConclusionThe trajectory of change in metabolic profile of body fluids before and after surgical resection may have potential clinical applications in lung cancer screening, as biomarkers for disease recurrence and exploration of novel targets for therapeutic intervention.